Effect of denosumab on bone mineral density and biochemical markers of bone turnover

Six-year results of a phase 2 clinical trial

Paul D. Miller, Rachel B. Wagman, Munro Peacock, E. Michael Lewiecki, Michael A. Bolognese, Richard L. Weinstein, Beiying Ding, Javier San Martin, Michael R. McClung

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Context: This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass. Objective: Our objective was to describe changes in bone mineral density (BMD) and bone turnover markers as well as safety with 6 yr of denosumab treatment. Design: We conducted an ongoing 4-yr, open-label, single-arm, extension study of a dose-ranging phase 2 trial. This paper reports a 2-yr interim analysis representing up to 6 yr of continuous denosumab treatment. Setting: This multicenter study was conducted at 23 U.S. centers. Patients: Of the 262 subjects who completed the parent study, 200 enrolled in the study extension and 178 (89%) completed the first 2 yr. Intervention: All subjects received denosumab 60 mg sc every 6 months. Main Outcome Measures:WeevaluatedBMDat the lumbar spine, total hip, femoral neck, and one third radius; biochemical markers of bone turnover; and safety, reported as adverse events. Results: Over a period of 6 yr, continuous treatment with denosumab resulted in progressive gains in BMD in postmenopausal women with low bone mass. Reduction in bone resorption was sustained over the course of continuous treatment. Independent of past treatment and discontinuation period, subjects demonstrated responsiveness to denosumab therapy as measured by BMD and bone turnover markers. The safety profile of denosumab did not change over time. Conclusions: In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass.

Original languageEnglish
Pages (from-to)394-402
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Bone Remodeling
Bone Density
Minerals
Bone
Biomarkers
Clinical Trials
Bone and Bones
Safety
Therapeutics
Denosumab
Femur Neck
Bone Resorption
Multicenter Studies
Hip
Spine
Outcome Assessment (Health Care)
Labels

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of denosumab on bone mineral density and biochemical markers of bone turnover : Six-year results of a phase 2 clinical trial. / Miller, Paul D.; Wagman, Rachel B.; Peacock, Munro; Lewiecki, E. Michael; Bolognese, Michael A.; Weinstein, Richard L.; Ding, Beiying; San Martin, Javier; McClung, Michael R.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 96, No. 2, 02.2011, p. 394-402.

Research output: Contribution to journalArticle

Miller, Paul D. ; Wagman, Rachel B. ; Peacock, Munro ; Lewiecki, E. Michael ; Bolognese, Michael A. ; Weinstein, Richard L. ; Ding, Beiying ; San Martin, Javier ; McClung, Michael R. / Effect of denosumab on bone mineral density and biochemical markers of bone turnover : Six-year results of a phase 2 clinical trial. In: Journal of Clinical Endocrinology and Metabolism. 2011 ; Vol. 96, No. 2. pp. 394-402.
@article{12afc32d5a4641358edaadb0ef6182e0,
title = "Effect of denosumab on bone mineral density and biochemical markers of bone turnover: Six-year results of a phase 2 clinical trial",
abstract = "Context: This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass. Objective: Our objective was to describe changes in bone mineral density (BMD) and bone turnover markers as well as safety with 6 yr of denosumab treatment. Design: We conducted an ongoing 4-yr, open-label, single-arm, extension study of a dose-ranging phase 2 trial. This paper reports a 2-yr interim analysis representing up to 6 yr of continuous denosumab treatment. Setting: This multicenter study was conducted at 23 U.S. centers. Patients: Of the 262 subjects who completed the parent study, 200 enrolled in the study extension and 178 (89{\%}) completed the first 2 yr. Intervention: All subjects received denosumab 60 mg sc every 6 months. Main Outcome Measures:WeevaluatedBMDat the lumbar spine, total hip, femoral neck, and one third radius; biochemical markers of bone turnover; and safety, reported as adverse events. Results: Over a period of 6 yr, continuous treatment with denosumab resulted in progressive gains in BMD in postmenopausal women with low bone mass. Reduction in bone resorption was sustained over the course of continuous treatment. Independent of past treatment and discontinuation period, subjects demonstrated responsiveness to denosumab therapy as measured by BMD and bone turnover markers. The safety profile of denosumab did not change over time. Conclusions: In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass.",
author = "Miller, {Paul D.} and Wagman, {Rachel B.} and Munro Peacock and Lewiecki, {E. Michael} and Bolognese, {Michael A.} and Weinstein, {Richard L.} and Beiying Ding and {San Martin}, Javier and McClung, {Michael R.}",
year = "2011",
month = "2",
doi = "10.1210/jc.2010-1805",
language = "English",
volume = "96",
pages = "394--402",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Effect of denosumab on bone mineral density and biochemical markers of bone turnover

T2 - Six-year results of a phase 2 clinical trial

AU - Miller, Paul D.

AU - Wagman, Rachel B.

AU - Peacock, Munro

AU - Lewiecki, E. Michael

AU - Bolognese, Michael A.

AU - Weinstein, Richard L.

AU - Ding, Beiying

AU - San Martin, Javier

AU - McClung, Michael R.

PY - 2011/2

Y1 - 2011/2

N2 - Context: This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass. Objective: Our objective was to describe changes in bone mineral density (BMD) and bone turnover markers as well as safety with 6 yr of denosumab treatment. Design: We conducted an ongoing 4-yr, open-label, single-arm, extension study of a dose-ranging phase 2 trial. This paper reports a 2-yr interim analysis representing up to 6 yr of continuous denosumab treatment. Setting: This multicenter study was conducted at 23 U.S. centers. Patients: Of the 262 subjects who completed the parent study, 200 enrolled in the study extension and 178 (89%) completed the first 2 yr. Intervention: All subjects received denosumab 60 mg sc every 6 months. Main Outcome Measures:WeevaluatedBMDat the lumbar spine, total hip, femoral neck, and one third radius; biochemical markers of bone turnover; and safety, reported as adverse events. Results: Over a period of 6 yr, continuous treatment with denosumab resulted in progressive gains in BMD in postmenopausal women with low bone mass. Reduction in bone resorption was sustained over the course of continuous treatment. Independent of past treatment and discontinuation period, subjects demonstrated responsiveness to denosumab therapy as measured by BMD and bone turnover markers. The safety profile of denosumab did not change over time. Conclusions: In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass.

AB - Context: This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass. Objective: Our objective was to describe changes in bone mineral density (BMD) and bone turnover markers as well as safety with 6 yr of denosumab treatment. Design: We conducted an ongoing 4-yr, open-label, single-arm, extension study of a dose-ranging phase 2 trial. This paper reports a 2-yr interim analysis representing up to 6 yr of continuous denosumab treatment. Setting: This multicenter study was conducted at 23 U.S. centers. Patients: Of the 262 subjects who completed the parent study, 200 enrolled in the study extension and 178 (89%) completed the first 2 yr. Intervention: All subjects received denosumab 60 mg sc every 6 months. Main Outcome Measures:WeevaluatedBMDat the lumbar spine, total hip, femoral neck, and one third radius; biochemical markers of bone turnover; and safety, reported as adverse events. Results: Over a period of 6 yr, continuous treatment with denosumab resulted in progressive gains in BMD in postmenopausal women with low bone mass. Reduction in bone resorption was sustained over the course of continuous treatment. Independent of past treatment and discontinuation period, subjects demonstrated responsiveness to denosumab therapy as measured by BMD and bone turnover markers. The safety profile of denosumab did not change over time. Conclusions: In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass.

UR - http://www.scopus.com/inward/record.url?scp=79951689707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951689707&partnerID=8YFLogxK

U2 - 10.1210/jc.2010-1805

DO - 10.1210/jc.2010-1805

M3 - Article

VL - 96

SP - 394

EP - 402

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -